ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the
"Corporation") announced today that it will launch fibrinogen for commercial
sales during the fourth quarter of 2014 after its successful scale-up at its
Laval based plasma purification facility, ProMetic BioProduction Inc. ("PBP").
This follows the previously disclosed proteins already scheduled for production
at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin. 


Sales of fibrinogen manufactured at commercial scale to pharmaceutical companies
as a GMP product will be starting in the fourth quarter of 2014, 6 months ahead
of the originally anticipated timeline. The fibrinogen protein has many
commercial applications ranging from harvesting and culturing stem cells to use
in wound healing products, hemostatic bandages and drug delivery systems. The
worldwide market for fibrinogen exceeds $500 million per year. The Corporation
is already in discussion with potential users of the product about making
initial supplies in the fourth quarter of 2014.


"There is a growing market for fibrinogen used in various commercial
applications that do not require regulatory authorization and we expect revenue
contribution to start as soon as the fourth quarter 2014", said Mr. Pierre
Laurin, President and Chief Executive Officer of ProMetic who also added "We are
also considering a clinical regulatory pathway to support the use of fibrinogen
for specific rare and unmet medical conditions". 


ProMetic's proprietary and proven PPPS(TM) platform has consistently delivered
higher recovery yield for several proteins, including fibrinogen which has a
production yield exceeding double that of the industry average. Prometic is also
further leveraging its PPPS(TM) platform to enable the manufacturing of two
other orphan drugs in 2014.


About Fibrinogen

Fibrinogen, also called Factor I, is a blood plasma protein produced by the
liver that plays an important role in blood coagulation. Blood coagulation is a
process in which several components of the blood form a clot. When blood escapes
from a rupture in a blood vessel, coagulation is triggered. Several proteins,
called coagulation factors, go into action to produce thrombin. The thrombin
then converts fibrinogen to fibrin. Fibrin produced from fibrinogen is the main
protein in a blood clot. It surrounds the cells in the blood and plasma and
helps form the clot. The resulting clot, which is stabilized by Factor XIII,
remains intact from 10 to 14 days, the time required for healing to take place.


About ProMetic Life Sciences Inc. 

ProMetic Life Sciences Inc. (www.prometic.com) is a long established
biopharmaceutical company with globally recognized expertise in bioseparations,
plasma-derived therapeutics and small-molecule drug development. ProMetic offers
its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base
of industry leaders and uses its own affinity technology that provides for
highly efficient extraction and purification of therapeutic proteins from human
plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic
is also active in developing its own novel small-molecule therapeutic products
targeting unmet medical needs in the field of fibrosis, cancer and autoimmune
diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D
facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK
and business development activities in the U.S., Europe and Asia.


Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations in ProMetic's Annual Information Form for the year ended December
31, 2013, under the heading "Risk and Uncertainties related to ProMetic's
business". As a result, we cannot guarantee that any forward-looking statement
will materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of future
events or for any other reason, unless required by applicable securities laws
and regulations. All amounts are in Canadian dollars unless indicated otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
p.laurin@prometic.com
+1.450.781.0115


Frederic Dumais
Director, Communications and
Investor Relations
ProMetic Life Sciences
f.dumais@prometic.com
+1.450.781.0115